Stephanie Peck
Associate Clinical Professor of Psychiatry at the University of California, San Diego; Clinical Psychologist and Director of Intensive Family Treatments at the UC San Diego Eating Disorders Center
Data updated
Research Footprint
Stephanie Peck appears in 5 tracked papers (2022–2025), most studied alongside Psilocybin, across Treatment-Resistant Depression (TRD), Depressive Disorders and Suicidality.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Ekaterina Malievskaia and Nadav Liam Modlin.
Background & Research
Stephanie Knatz Peck, PhD, is a clinical psychologist and associate clinical professor of psychiatry at UC San Diego. She directs Intensive Family Treatments at the UC San Diego Eating Disorders Center and conducts research on evidence-based treatments for eating disorders and novel psychiatric interventions, including psychedelic-assisted psychotherapy. Her work has included serving as a senior clinical consultant and content developer for Compass Pathways’ therapist training and psychological support programs.
Key Impact
She is a key clinician-scientist in psychedelic-assisted psychotherapy, contributing to psilocybin studies for treatment-resistant depression and anorexia nervosa and helping develop Compass’ psychological support model.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Stephanie Peck is associated with.
University of California San Diego
academicThe Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →